PHOTO
Bahrain – Investcorp, a leading global provider and manager of alternative investment products, today announced that it has acquired Sanos Group (“Sanos”), a leading provider of specialized clinical trial services to the global pharmaceutical and biotechnology industry.
Based in Denmark, Sanos is a global Contract Research Organization (“CRO”) providing value-added services to pharma, biotech and research organizations to help plan and conduct clinical trials, a critical part in the development of new drugs and treatments. Sanos Group consists of a CRO specialized in osteoarthritis (“OA”) and a Site Management Organization (“SMO”) with a broader indication range focusing on lifestyle and age-related diseases. Sanos has built a worldwide reputation for its scientific expertise, ability to recruit patients and track record of executing safe and efficient clinical trials.
The global CRO market is estimated to be approximately US $50 billion and is growing at approximately 10% per annum, driven by increasing R&D spend to develop new drugs and treatments as well as a trend by pharma and biotech companies to outsource the clinical trials for new drugs to CROs. Sanos’ scientific leadership in OA, a highly prevalent disease that currently affects more than 240 million people worldwide, together with its strong network of key opinion leaders and its integrated value chain with three owned research clinics in Denmark, makes it a preferred strategic partner for OA clinical trials. Investcorp plans to support Sanos’ efforts to capitalize on its multiple market opportunities by further increasing its penetration in OA while looking to grow into clinical trials for other therapeutic areas and expanding its research clinics network into new geographies.
Daniel Lopez-Cruz, Head of Private Equity, Europe at Investcorp, said; “Sanos has all the key attributes that we look for in potential investments. It is an entrepreneurial organization with a clearly differentiated value proposition as well as a leading market position in a growing, resilient and mission-critical industry. Sanos has established itself as the partner of choice for pharma and biotech companies looking to conduct clinical trials for osteoarthritis, a condition for which there is currently a very high unmet medical need given the large and growing population of people being affected by it and the fact that there is no cure for it at the moment. Leveraging its strong OA franchise, we believe that Sanos has significant potential for international expansion through new research clinics in the US -the largest market for clinical trials- and other European countries beyond Denmark. We look forward to partnering with Sanos’ experienced management team to realize the opportunities ahead.”
Tarek AlMahjoub, Head of UAE and Oman for Investcorp’s Private Wealth said: “At Investcorp, we focus on investment opportunities in mid-sized companies with strong growth potential, solid cash flow, prominent positioning within their industry, and best-in-class management teams with a robust track record. We believe that Sanos aligns with all of our key criteria and we look forward to supporting the company’s growth and expansion.”
Investcorp has an established history of investing in the healthcare sector globally. The acquisition of Sanos is Investcorp’s 11th investment in the healthcare sector and the third in Europe, following its acquisition of a majority stake in Cambio Healthcare Systems, which operates in the Electronic Health Records market, and Acura, a network dedicated to providing accessible and high quality dental care across Germany.
-Ends-
About Investcorp
Investcorp is a global investment manager, specializing in alternative investments across private equity, real estate, credit, absolute return strategies, GP stakes and infrastructure. Since our inception in 1982, we have focused on generating attractive returns for our clients while creating long-term value in our investee companies and for our shareholders as a prudent and responsible investor.
We invest a meaningful portion of our own capital in products we offer to our clients, ensuring that our interests are aligned with our stakeholders, including the communities that we operate within, towards driving sustainable value creation. We take pride in partnering with our clients to deliver tailored solutions for their needs, utilizing a disciplined investment process, employing world-class talent and combining the resources of a global institution with an innovative, entrepreneurial approach.
Investcorp has today a presence in 12 countries across the US, Europe, GCC and Asia, including India, China and Singapore. As of June 30, 2020, Investcorp Group had US $32.2 billion in total AUM, including assets managed by third party managers, and employed approximately 450 people from 44 nationalities globally across its offices. For further information, visit www.investcorp.com and follow us @Investcorp on LinkedIn, Twitter and Instagram.
Media Contacts:
Investcorp
Nada Abdulghani
nabdulghani@investcorp.com
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
